CN110613708A - 二氢丹参酮ⅰ用作p53激动剂和信号传导及转录激活因子3抑制剂的用途 - Google Patents
二氢丹参酮ⅰ用作p53激动剂和信号传导及转录激活因子3抑制剂的用途 Download PDFInfo
- Publication number
- CN110613708A CN110613708A CN201910585525.9A CN201910585525A CN110613708A CN 110613708 A CN110613708 A CN 110613708A CN 201910585525 A CN201910585525 A CN 201910585525A CN 110613708 A CN110613708 A CN 110613708A
- Authority
- CN
- China
- Prior art keywords
- dihydrotanshinone
- signal transduction
- liver
- application
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HARGZZNYNSYSGJ-UHFFFAOYSA-N 1,2 dihydrotanshinquinone Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)CO1 HARGZZNYNSYSGJ-UHFFFAOYSA-N 0.000 title claims abstract description 124
- HARGZZNYNSYSGJ-JTQLQIEISA-N Dihydrotanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2[C@@H](C)CO1 HARGZZNYNSYSGJ-JTQLQIEISA-N 0.000 title claims abstract description 124
- 238000013518 transcription Methods 0.000 title claims abstract description 16
- 230000035897 transcription Effects 0.000 title claims abstract description 16
- 230000019491 signal transduction Effects 0.000 title claims abstract description 15
- 239000012190 activator Substances 0.000 title claims abstract description 14
- 239000000556 agonist Substances 0.000 title claims abstract description 13
- 239000003112 inhibitor Substances 0.000 title claims abstract description 13
- 206010019668 Hepatic fibrosis Diseases 0.000 claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 26
- 210000004185 liver Anatomy 0.000 claims abstract description 22
- 230000006907 apoptotic process Effects 0.000 claims abstract description 18
- 210000004024 hepatic stellate cell Anatomy 0.000 claims abstract description 16
- 239000000835 fiber Substances 0.000 claims abstract description 10
- 102000008186 Collagen Human genes 0.000 claims abstract description 9
- 108010035532 Collagen Proteins 0.000 claims abstract description 9
- 229920001436 collagen Polymers 0.000 claims abstract description 9
- 230000004913 activation Effects 0.000 claims abstract description 8
- 238000009825 accumulation Methods 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 230000020411 cell activation Effects 0.000 claims abstract description 3
- 230000004663 cell proliferation Effects 0.000 claims abstract description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 230000035755 proliferation Effects 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 51
- 102000004169 proteins and genes Human genes 0.000 abstract description 51
- 239000002207 metabolite Substances 0.000 abstract description 39
- 238000002474 experimental method Methods 0.000 abstract description 18
- 206010067125 Liver injury Diseases 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 13
- 231100000753 hepatic injury Toxicity 0.000 abstract description 11
- 230000003908 liver function Effects 0.000 abstract description 11
- 238000001262 western blot Methods 0.000 abstract description 10
- 241000700159 Rattus Species 0.000 abstract description 9
- 238000003012 network analysis Methods 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 3
- 238000012404 In vitro experiment Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 51
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 32
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 30
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 30
- 208000019425 cirrhosis of liver Diseases 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 25
- 230000000694 effects Effects 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 19
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 12
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 11
- 238000011282 treatment Methods 0.000 description 9
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 8
- 108010082126 Alanine transaminase Proteins 0.000 description 8
- 238000003032 molecular docking Methods 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 5
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 5
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 5
- 102000001187 Collagen Type III Human genes 0.000 description 5
- 108010069502 Collagen Type III Proteins 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 5
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000005065 mining Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 229960003787 sorafenib Drugs 0.000 description 5
- 238000012795 verification Methods 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- 102000000503 Collagen Type II Human genes 0.000 description 4
- 108010041390 Collagen Type II Proteins 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- KXNYCALHDXGJSF-UHFFFAOYSA-N dihydroisotanshinone I Natural products CC1=CC=CC2=C(C(C=3OCC(C=3C3=O)C)=O)C3=CC=C21 KXNYCALHDXGJSF-UHFFFAOYSA-N 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010040476 FITC-annexin A5 Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- -1 liver protection Chemical compound 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- BDUHCSBCVGXTJM-UHFFFAOYSA-N 4-[[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazol-1-yl]-oxomethyl]-2-piperazinone Chemical compound CC(C)OC1=CC(OC)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)N1C(=O)N1CC(=O)NCC1 BDUHCSBCVGXTJM-UHFFFAOYSA-N 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 241000995051 Brenda Species 0.000 description 1
- CMDLYHXLYMIGIH-UHFFFAOYSA-N C.S.S Chemical compound C.S.S CMDLYHXLYMIGIH-UHFFFAOYSA-N 0.000 description 1
- 101100361281 Caenorhabditis elegans rpm-1 gene Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 206010057573 Chronic hepatic failure Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102100039928 Gamma-interferon-inducible protein 16 Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 101000960209 Homo sapiens Gamma-interferon-inducible protein 16 Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101700056750 PAK1 Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 101100299505 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ptn1 gene Proteins 0.000 description 1
- 102100031206 Serine/threonine-protein kinase N1 Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910001347 Stellite Inorganic materials 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000001587 cholestatic effect Effects 0.000 description 1
- AHICWQREWHDHHF-UHFFFAOYSA-N chromium;cobalt;iron;manganese;methane;molybdenum;nickel;silicon;tungsten Chemical compound C.[Si].[Cr].[Mn].[Fe].[Co].[Ni].[Mo].[W] AHICWQREWHDHHF-UHFFFAOYSA-N 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000003331 infrared imaging Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000013424 sirius red staining Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及医药技术领域,具体是二氢丹参酮Ⅰ在制备P53激动剂和信号传导及转录激活因子3抑制剂中的应用。本发明利用网络药理学和代谢组学数据构建“二氢丹参酮Ⅰ潜在靶标‑肝纤维化相关蛋白‑代谢物相关蛋白‑代谢物”网络,经网络分析后识别出二氢丹参酮Ⅰ最相关靶蛋白信号传导及转录激活因子3和P53,并通过细胞增殖、细胞凋亡、SPR和Western blotting等体外实验和TAA诱导肝纤维化大鼠的体内实验验证二氢丹参酮Ⅰ通过作用信号传导及转录激活因子3和P53靶标,抑制肝星状细胞活化,并降低肝脏中Ⅰ型和Ⅲ型胶原纤维的积累,发挥改善肝功能、降低肝损伤和抗肝纤维化的作用。
Description
技术领域
本发明涉及医药技术领域,是提供二氢丹参酮Ⅰ的新的医药用途,具体是 二氢丹参酮Ⅰ用作P53激动剂和信号传导及转录激活因子3(STAT3)抑制剂 的用途。
背景技术
肝纤维化是一种可逆的损伤-修复应答反应,是多种致病因素引起肝损伤 时的病理反应,是肝损伤发展到肝硬化的必经阶段,其特征是肝损伤后ECM 大量增生。肝纤维化并不是一个独立的疾病,造成肝纤维化的主要原因包括病 毒性肝炎、慢性酒精中毒、非酒精性的脂肪肝炎、化学毒物或药物、胆汁淤积 性疾病,自身免疫性肝炎和遗传性代谢等疾病。由于ECM积累形成纤维性的 瘢痕导致肝脏结构扭曲,随后肝再生结节发展成为肝硬化。肝硬化导致肝细胞 功能障碍,肝内血流阻力增加,进而引起肝功能不全、门静脉高压症、急慢性 肝功能衰竭和肝细胞癌。目前,在我国约有70%的肝纤维化患者发展成肝癌。 而肝移植是肝纤维化晚期-肝硬化患者唯一可用的治疗方法,因此,亟待新的 抗纤维化治疗策略。
中药蕴含大量结构多样的天然活性成分,是抗肿瘤新药研发的重要来源。 二氢丹参酮Ⅰ是丹参中的亲脂性成分,被认为是肝纤维化的潜在治疗药物。已 有的研究报道了二氢丹参酮Ⅰ具有的一些生物学功能,包括肝脏保护作用、抗 炎作用,心脏保护作用和抗癌的作用。(Xu J K,Hiroshi K,Zheng J J,Jiang T,Yao X S.[Protective effect oftanshinones against liver injury in mice loaded with restraint stress][J].Yaoxue xue bao=Acta pharmaceutica Sinica,2006,41(7): 631-5.Wang F,Ma J,Wang KS,Mi C,Lee J J,Jin X.Blockade of TNF-alpha-induced NF-kappaB signalingpathway and anti-cancer therapeutic response of dihydrotanshinone I[J].International immunopharmacology,2015, 28(1):764-72.Wei Y,Xu M,Ren Y,Lu G,XuY,Song Y,Ji H.The cardioprotection of dihydrotanshinone I against myocardialischemia-reperfusion injury via inhibition of arachidonic acid omega-hydroxylase[J].Canadian journal of physiology and pharmacology,2016,94(12):1267-75.Wang L,Hu T,Shen J, Zhang L,Chan R L,Lu L,Li M,Cho C H,Wu WK.Dihydrotanshinone I induced apoptosis and autophagy through caspasedependent pathway in colon cancer[J]. Phytomedicine:international journal ofphytotherapy and phytopharmacology, 2015,22(12):1079-87.)。然而,其抗组织器官纤维化直接作用靶蛋白尚不完 全明确。
发明内容
本发明的目的在于利用“蛋白-代谢物”分析策略,将网络药理学和代谢组 学结合,筛选出二氢丹参酮Ⅰ最相关靶蛋白;并通过实验验证该靶蛋白。
本发明的第一方面,提供二氢丹参酮Ⅰ在制备P53激动剂和信号传导及转 录激活因子3(STAT3)抑制剂中的应用。
进一步的,本发明提供二氢丹参酮Ⅰ在制备P53激动剂中的应用。
本发明实验结果表明,二氢丹参酮Ⅰ通过与P53结合,发挥其对LX-2细 胞和T6细胞活性的抑制作用。Western blotting结果分析显示二氢丹参酮Ⅰ可 以剂量依赖性地促进LX-2细胞和T6细胞中P53和p-P53的表达。
进一步的,本发明提供二氢丹参酮Ⅰ在制备信号传导及转录激活因子3 (STAT3)抑制剂中的应用。
本发明实验结果表明,二氢丹参酮Ⅰ通过与STAT3蛋白结合,发挥其对 LX-2和T6细胞活性的抑制作用。二氢丹参酮Ⅰ可以剂量依赖性地抑制LX-2 细胞中STAT3和p-STAT3的表达,二氢丹参酮Ⅰ虽不能剂量依赖性地抑制T6 细胞中STAT3的表达,但能明显的抑制其p-STAT3的表达。
本发明还提供二氢丹参酮Ⅰ在制备促进肝星状细胞凋亡,抑制肝星状细胞 活化和增殖的药物中的应用。
进一步的,二氢丹参酮Ⅰ通过作用P53和STAT3,促进肝星状细胞凋亡, 抑制肝星状细胞活化和增殖。
本发明还提供二氢丹参酮Ⅰ在制备降低肝脏中Ⅰ型和Ⅲ型胶原纤维的积 累的药物中的应用。
进一步的,二氢丹参酮Ⅰ可以改善由TAA诱导的肝损伤,并具有改善肝 功能、降低肝损伤和治疗肝纤维化的作用。
本发明的第二方面,提供二氢丹参酮Ⅰ作为P53激动剂在制备肝纤维化治 疗药物中的应用。
本发明的第三方面,提供二氢丹参酮Ⅰ作为信号传导及转录激活因子3 (STAT3)抑制剂在制备肝纤维化治疗药物中的应用。
本发明的第四方面,提供二氢丹参酮Ⅰ作为P53激动剂和信号传导及转录 激活因子3(STAT3)抑制剂在制备肝纤维化治疗药物中的应用。
本发明的第五方面,提供二氢丹参酮Ⅰ作为P53激动剂在制备动脉粥样硬 化、乳腺癌、或结肠癌治疗药物中的应用(Biao Hao,Yan Xiao,Fang Song, Xiangshu Long,JingHuang,Maobo Tian,Shiyan Deng,and Qiang Wu, Metformin-induced activation ofAMPK inhibits the proliferation and migration of human aortic smooth musclecells through upregulation of p53 and IFI16.Int J Mol Med.2018 Mar;41(3):1365–1376.Akaogi K,Ono W,Hayashi Y,Kishimoto H, Yanagisawa J.MYBBP1Asuppresses breast cancer tumorigenesis by enhancing the p53 dependentanoikis.BMC Cancer.2013 Feb 7;13:65.Makovski A,Yaffe E, Shpungin S,NirU.Down-regulation of Fer induces ROS levels accompanied by ATM and p53activation in colon carcinoma cells.Cell Signal.2012 Jul;24(7):1369-74.)。
本发明的第六方面,提供二氢丹参酮Ⅰ作为信号传导及转录激活因子3 (STAT3)抑制剂在制备膀胱癌、食管癌、或前列腺癌治疗药物中的应用(Tsujita Y,Horiguchi A,Tasaki S,Isono M,Asano T,Ito K,Asano T,Mayumi Y,Kushibiki T.STAT3 inhibitionby WP1066 suppresses the growth and invasiveness of bladder cancercells.Oncol Rep.2017 Oct;38(4):2197-2204.Zhou C,Ma J,Su M,Shao D, Zhao J,ZhaoT,Song Z,Meng Y,Jiao P.Down-regulation of STAT3 induces the apoptosis and G1cell cycle arrest in esophageal carcinoma ECA109 cells.Cancer Cell Int.2018Apr 4;18:53.Jeon YJ,Jung SN,Chang H,Yun J,Lee CW,Lee J, Choi S,Nash O,Han DC,Kwon BM.Artocarpus altilis(Parkinson)Fosberg Extracts and GeranylDihydrochalcone Inhibit STAT3 Activity in Prostate Cancer DU145Cells.Phytother Res.2015 May;29(5):749-56.)。
本发明有益效果在于:
肝纤维化是大多数慢性肝病中常见的病理过程。本发明利用网络药理学和 代谢组学数据构建“二氢丹参酮Ⅰ潜在靶标-肝纤维化相关蛋白-代谢物相关蛋 白-代谢物”网络,经网络分析后识别出二氢丹参酮Ⅰ最相关靶蛋白STAT3和 P53,并通过细胞增殖、细胞凋亡、SPR和Western blotting等体外实验和TAA 诱导肝纤维化大鼠的体内实验验证二氢丹参酮Ⅰ通过作用STAT3和P53靶标, 抑制肝星状细胞活化,并降低肝脏中Ⅰ型和Ⅲ型胶原纤维的积累,发挥改善肝 功能、降低肝损伤和抗肝纤维化的作用。
二氢丹参酮Ⅰ在体内外对肝纤维化都具有一定的治疗效果,并具有改善肝 功能、降低和改善肝损伤的作用,可成为改善肝功能、降低肝损伤和治疗肝纤 维化的一种新型治疗策略。
附图说明
图1.用膜联蛋白V-FITC和PI染色细胞的流式细胞术分析二氢丹参酮Ⅰ 诱导LX-2细胞(A/B)和T6细胞(C/D)的凋亡。以上实验重复三次,并以平均值 (±SD)表示。*P<0.05,**P<0.01,***P<0.001表示与对照组相比差异有 统计学差异。
图2.二氢丹参酮Ⅰ靶蛋白-肝纤维化相关蛋白-代谢物相关蛋白-代谢物网 络图,图中圆圈中分别表示P53和STAT3靶蛋白。
图3.(A)P53-肝纤维化相关蛋白-代谢物相关蛋白-代谢物网络;(B) 二氢丹参酮Ⅰ与P53相互作用的SPR分析,P53使用一组连续稀释液一式三份 进行动力学测量。该数据是三次独立实验的代表。(C)二氢丹参酮Ⅰ处理后 LX-2细胞(a)和T6细胞(b)对P53、p-P53Western blotting分析。
图4.(A)STAT3-肝纤维化相关蛋白-代谢物相关蛋白-代谢物网络;(B) 二氢丹参酮Ⅰ与STAT3相互作用的SPR分析。使用一组连续稀释液一式三份 进行动力学测量。该数据是三次独立实验的代表。(C)二氢丹参酮Ⅰ处理后 LX-2细胞(a)和T6细胞(b)中STAT3、p-STAT3 Western blotting分析。
图5.二氢丹参酮Ⅰ对血清肝功能标志物、肝脏形态和结构的影响。(A、 B、C、D)分别表示血清中ALT、AST、ALP和γ-GT的值。(E)H&E染色, 放大倍数×100。(F)Sirius Red的三色染色,放大倍数×100。(G、H)分别 表示肝脏中Ⅰ型和Ⅲ型胶原纤维的面积。以上实验重复三次,并以平均值 (±SD)表示。*P<0.05,**P<0.01,***P<0.001表示与对照组相比差异有统计学差异;#P<0.05,##P<0.01,###P<0.001表示与模型组相比差异有统计 学差异。
具体实施方式
下面结合实施例对本发明提供的具体实施方式作详细说明。
实施例1:
一、试剂与方法:
(一)试剂
二氢丹参酮Ⅰ(纯度≥98%)、索拉非尼(纯度≥98%)购自上海一飞生物 科技有限公司,硫代乙酰胺购自东京化成工业株式会社(上海),Nutlin3购 自于Selleck Chemicals(美国),LX-2细胞(人肝星状细胞)和T6细胞(大 鼠肝星状细胞)购自上海复旦IBS细胞资源中心。青链霉素(PS)、磷酸盐缓 冲溶液(PBS)、0.25%胰蛋白酶购自康宁公司(美国);胎牛血清(FBS)购 自GIBCO公司(美国);培养基购自Sigma(美国)。细胞裂解液、单克隆 抗体STAT3、P-STAT3、P-P53、GADPH兔抗获自Cell Signaling Technology(美 国),P53、β-actin鼠抗购自圣克鲁斯生物技术公司(美国),IRDye680RD 缀合羊抗兔和IRDye800RD羊抗鼠二抗购自LI-COR Biosciences(美国)。
(二)实验方法
1、化学信息数据库的构建
首先,在美国国家生物技术信息中心Pubmed数据中进行文本挖掘,我们 获取了271个二氢丹参酮Ⅰ相关的潜在靶标,然后在UniProt Database和RCSB Protein Data Bank数据库中下载每种靶蛋白的晶体结构。
2、二氢丹参酮Ⅰ靶标的预测
采用相似性匹配和分子对接的方法筛选二氢丹参酮Ⅰ的潜在靶标。首先运 用相似性匹配的方法,由于具有相似结构的药物可能具有共同的靶标,因此, 我们使用药物相似性搜索数据库-ChEMBL寻找与二氢丹参酮Ⅰ结构相似的化 合物,为获得更准确结果仅挑选出具有高相似性得分(≥0.9)的化合物;此外, 还在ChEMBL中搜索这些相似化合物的靶标,以假设这些可能是二氢丹参酮 Ⅰ的靶标。其次,采用分子对接的方法,分子对接不仅可用于预测药物与其靶 蛋白的结合位点和姿势,还可用于评估其结合亲和力(Kitchen D B,Decornez H, Furr J R,Bajorath J.Docking and scoring in virtual screening fordrug discovery: methods and applications[J].Nature reviews Drug discovery,2004,3(11): 935-49.)。随后,我们在分子对接软件Discovery Studio 3.08中使用了libdock 来获得二氢丹参酮Ⅰ相关的潜在靶标和二氢丹参酮Ⅰ之间对接打分。并将靶蛋 白与其结合共结晶配体之间的对接打分视为阈值,如果对接打分高于阈值,则 此蛋白将被视为二氢丹参酮Ⅰ潜在靶标。
3、代谢物信息的获取
通过在Pubmed数据中进行文本挖掘,我们获取了肝纤维化的相关代谢物。 基于BRENDA数据库可以提供调节代谢物的上游蛋白,我们在此数据库中检 索到肝纤维化相关代谢物的蛋白。
4、网络的构建与分析
基于已获取的二氢丹参酮Ⅰ潜在靶标、肝纤维化靶标、代谢物相关蛋白及 代谢物相关数据,在Cytoscape 3.5.1(Smoot M E,Ono K,Ruscheinski J,Wang P L,IdekerT.Cytoscape 2.8:new features for data integration and network visualization[J].Bioinformatics(Oxford,England),2011,27(3):431-2.)中构建“二 氢丹参酮Ⅰ潜在靶标-肝纤维化相关蛋白标-代谢物相关蛋白-代谢物”相互作用 网络,靶标或代谢物用节点表示,之间的相互作用关系用边表示。
5、细胞凋亡检测
LX-2细胞和T6在含有10%FBS、0.1%PS的培养基中培养,并在37℃、 5%CO2的孵箱中进行繁殖生长,培养基每2天换一次。取指数生长期的细胞 进行后续实验。使用膜联蛋白V-FITC凋亡检测试剂盒(杭州联科生物技术股 份有限公司)通过流式细胞术测定凋亡细胞。将细胞(2×105)接种在六孔板 的每个孔上,并用不同浓度的二氢丹参酮Ⅰ处理24h。收获漂浮和贴壁细胞并 在PBS中洗涤两次。将细胞重悬于PBS中,室温下在黑暗中用膜联蛋白V/FITC 染色细胞15min,然后加入碘化丙啶(PI)。使用FACS Calibur仪器(BectonDickinson,Mountain View,CA,USA)分析染色细胞。
6、表面等离子体共振(SPR)分析
采用Biacore T200仪器(GE Healthcare,Little Chalfont,Buckinghamshire,United Kingdom),使用PBS和5%DMSO流动相,通过应用1-(3-二甲基氨 基丙基)-3-乙基碳二亚胺/N-羟基琥珀酰亚胺交联反应,将信号转导与转录激 活因子3(STAT3,Abcam,英国)蛋白和P53(Abcam,英国)蛋白固定在 CM4芯片上,恒定流速为30mL/min。根据GEHealthcare提供的方案进行检测。 将化合物按梯度浓度(0.5-256μM)溶解在流动相中,注入通道中60s,然后解 离120s。使用BIA评估软件3.0(BIAcore)进行分析1:1结合模型的数据。
7、蛋白质的提取及Western blotting
将T6细胞和LX-2细胞接种于6孔板(每孔3×105个细胞)中过夜,然后 用各浓度的二氢丹参酮Ⅰ(溶于0.1%DMSO)处理24h。收集二氢丹参酮Ⅰ处 理的细胞在冰上用裂解缓冲液进行裂解。然后将裂解物在4℃下以12,000r/min 离心20min以除去不溶物质并在12%SDS-PAGE凝胶上分离。电泳后,将蛋白 质电转移到硝酸纤维素膜上,室温下用5%脱脂奶粉-TBST中封闭1h,将膜与 总STAT3(1:1000)、p-STAT3(1:1000)、P53(1:1000)、p-P53(1:1000)、GADPH(1:5000)一抗在4℃下孵育过夜,最后在室温下用HRP缀 合的山羊抗兔(1:10000)或山羊抗鼠二抗(1:10000)孵育2h。使用Odyssey 红外成像系统(LI-COR,UnitedStates)扫描分析蛋白灰度条带。实验中GADPH 作为内参。
8、动物实验
所有动物实验在海军军医大学动物实验中心遵循动物实验的标准操作规 范进行。在该研究中使用38只雄性SD大鼠(200-250g,中国科学院上海实验 动物中心),将大鼠在22±2℃,40-60%相对湿度,12h交替光/暗循环的条件 下笼养。将动物随机分成5组:对照组(n=6),硫代乙酰胺(Thioacetamide, TAA)模型组(n=8),TAA+二氢丹参酮Ⅰ(15mg/kg,n=8),TAA+二氢丹 参酮Ⅰ(30mg/kg,n=8),TAA+索拉非尼(n=8)。除对照组,其余每组连续 8周腹腔注射200mg/kg TAA(每周三次);从第5周开始,每天灌胃10mL/kg 的生理盐水(对照组/模型组)、15mg/kg的二氢丹参酮Ⅰ(低剂量组)、30mg/kg 的二氢丹参酮Ⅰ(高剂量组)和10mg/kg索拉非尼(阳性药组),持续四周。 对照组大鼠接受正常饮食,不注射TAA,持续8周。
最后一次灌胃24h后,腹腔注射10%水合氯醛将大鼠麻醉(0.3mL/100g), 腹腔主动脉取血,静置。全血以4000r·min-1离心10min取血清,在-80℃ 下储存直至测定。快速切除肝脏后,用冰冷的盐水冲洗并称重,然后将肝脏立 即放于液氮中快速冷冻并储存于-80℃直至分析。此外,将每个肝脏的一部分 固定在10%多聚甲醛中用于组织学观察。
9、血清生化与肝组织学
使用Hitachi 7100分析仪分析血清丙氨酸转氨酶(Alanine aminotrans, ALT),天冬氨酸转氨酶(Aspartate aminotransferase,AST),γ-谷氨酰转移 酶(γ-glutamyltransferase,γ-GT)和碱性磷酸酶(Alkaline phosphatase,ALP), 按照西唐生物科技有限公司(上海)试剂盒的操作说明进行检测。肝组织石蜡 切片用苏木精和曙红(Haematoxylin and eosin,H&E)及天狼猩红染色。在低 放大倍数(10×物镜,Olympus,IX73)下观察来自每只动物的组织切片,并 使用ImageJ分析以计算纤维化区域的百分比。
二、结果与讨论
(一)二氢丹参酮Ⅰ对LX-2细胞和T6细胞凋亡的影响
前期研究(Xing X,Chen S,Li L,Cao Y,Chen L,Wang X,Zhu Z.The ActiveComponents of Fuzheng Huayu Formula and Their Potential Mechanism of Actionin Inhibiting the Hepatic Stellate Cells Viability-A Network Pharmacology andTranscriptomics Approach.Front Pharmacol.2018 May 24;9:525.)已表明二氢丹参 酮Ⅰ可以明显抑制LX-2细胞和T6细胞的增殖,其IC50值分别是14.4和5.6μM。 为探究二氢丹参酮Ⅰ是否能引起细胞凋亡,采用流式细胞术进行检测。如图1 所示,二氢丹参酮Ⅰ分别作用LX-2细胞和T6细胞24h后发现,细胞凋亡率 随着二氢丹参酮Ⅰ浓度升高而增大。二氢丹参酮Ⅰ以0、2.5、5、10μM的浓度 作用于LX-2细胞时,其凋亡百分率(图1A/B)分别为4.6%、7.6%、16.6%和 20.5%(p<0.001);二氢丹参酮Ⅰ以0、5、10、20μM的浓度作用于T6细胞 时,其凋亡百分率(图1C/D)分别为3.8%、36.8%、59.8%和60.8%(p<0.001)。 结果表明二氢丹参酮Ⅰ能以不同程度诱导LX-2细胞和T6细胞凋亡,由此推 测二氢丹参酮Ⅰ可能通过促进肝星状细胞凋亡,进而抑制肝星状细胞活化。
(二)二氢丹参酮Ⅰ预测的靶标
基于文本挖掘已获得的79个肝纤维化相关靶标。采用分子对接和相似性 匹配识别了182个二氢丹参酮Ⅰ潜在靶标,其中158个靶标来自相似性匹配, 29个靶标来自分子对接。有趣的是,这两种方法都识别出的靶标有:STAT3、 PTN1、NF2L2、PAK1、MK08。并根据文本挖掘的数据整理了肝纤维化相关 蛋白和二氢丹参酮Ⅰ潜在靶标在其抗肝纤维化过程中发挥的作用(抑制或促进 作用)。
(三)代谢物信息的获取
在Pubmed数据库经过文本挖掘,找到35个肝纤维化相关的代谢物,我 们将这些代谢物输入到BREDNA数据库中,共检索到235个关于肝纤维化代 谢物相关的蛋白。基于文本挖掘的数据整理了肝纤维化相关代谢物在肝纤维化 过程中的变化(上调、下调变化)。
(四)网络的构建与分析
我们使用上述已获得的数据构建了“二氢丹参酮Ⅰ靶标-肝纤维化相关蛋 白-代谢物相关蛋白-代谢物”网络(图2),该网络中包含162个节点(18个二 氢丹参酮Ⅰ靶标、33个肝纤维化相关蛋白、85个代谢物相关蛋白和26个代谢 物)和719条边。网络中绿色和粉红色椭圆分别表示二氢丹参酮Ⅰ抗肝纤维化 过程中对靶蛋白的抑制和促进作用,青色和橘黄色的六边形分别表示肝纤维化 过程中相关靶蛋白下调和上调,浅蓝色椭圆形表示代谢物相关蛋白,深蓝色和 红色的矩形表示抗肝纤维化过程中相关代谢物发生下调和上调。
为提高二氢丹参酮Ⅰ靶蛋白识别的准确性,对“二氢丹参酮Ⅰ靶标-肝纤维 化相关蛋白-代谢物相关蛋白-代谢物”网络分析后,整理了与二氢丹参酮Ⅰ靶蛋 白相互作用蛋白的数量,如表1。一般来说,网络中与其相互作用的蛋白数量 越多,则该蛋白可能是该网络发挥作用的关键蛋白(Chen S,Jiang H,Cao Y, Wang Y,Hu Z,Zhu Z,Chai Y.Drug targetidentification using network analysis: Taking active components in Sinidecoction as an example[J].Scientific reports, 2016,6:24245.)。从表1中发现P53和STAT3在18个二氢丹参酮Ⅰ靶蛋白中 相互作用蛋白数量最多;由此我们推测P53和STAT3(图2中已标出)是二氢 丹参酮Ⅰ治疗肝纤维化过程中发挥作用的关键蛋白。因此,后续实验从验证二 氢丹参酮Ⅰ与P53和STAT3靶蛋白出发,进一步研究其对肝纤维化相关靶标、 代谢物相关蛋白以及代谢物的影响。
表1二氢丹参酮Ⅰ靶蛋白相互作用蛋白的数量
实施例2:二氢丹参酮Ⅰ作用P53靶蛋白的实验验证
基于“二氢丹参酮Ⅰ靶标-肝纤维化相关蛋白-代谢物相关蛋白-代谢物”网 络的分析结果,我们构建了“P53-肝纤维化相关蛋白-代谢物相关蛋白-代谢物” 网络(图3A),并推测二氢丹参酮Ⅰ可能通过作用P53靶蛋白发挥抗肝纤维 化作用。为了验证上述问题,我们通过SPR分析、细胞活性实验和Western blotting实验进行验证。
1、二氢丹参酮Ⅰ与P53靶蛋白结合分析
基于SPR技术检测二氢丹参酮Ⅰ与P53靶蛋白间结合的亲和力。实验结 果表明二氢丹参酮Ⅰ与P53靶蛋白间结合的Kd值为4.18μM,此结果与抑制细 胞活性实验的结果基本一致,表明二氢丹参酮Ⅰ通过与P53结合,发挥其对 LX-2细胞和T6细胞活性的抑制作用。
2、Western blotting验证P53相关靶蛋白
首先对“P53-肝纤维化相关蛋白-代谢物相关蛋白-代谢物”网络中P53蛋白 在LX-2和T6细胞中的表达进行实验验证。Western blotting结果分析显示二氢 丹参酮Ⅰ可以剂量依赖性地促进LX-2细胞和T6细胞(图3C-a/b)中P53和 p-P53的表达。
实施例3:二氢丹参酮Ⅰ作用STAT3的实验验证
基于“二氢丹参酮Ⅰ靶标-肝纤维化相关蛋白-代谢物相关蛋白-代谢物”网 络的分析结果,我们构建了“STAT3-肝纤维化靶蛋白-代谢物相关蛋白-代谢物” 网络(图4A),并推测二氢丹参酮Ⅰ可能通过作用STAT3靶蛋白发挥抗肝纤 维化作用。为了验证上述问题,我们通过SPR分析和Western blotting实验进 行验证。
1、二氢丹参酮Ⅰ与STAT3结合的SPR分析
SPR可以进行化合物与蛋白的结合检测,因此可以于检测二氢丹参酮Ⅰ与 STAT3靶蛋白间结合的亲和力。SPR结果表明二氢丹参酮Ⅰ与STAT3靶蛋白 之间Kd值为5.66μM,此结果与抑制细胞活性实验的结果基本一致,表明二氢 丹参酮Ⅰ通过与STAT3蛋白结合,发挥其对LX-2和T6细胞活性的抑制作用。
2、Western blotting验证STAT3相关靶标
首先对“STAT3-肝纤维化相关蛋白-代谢物相关蛋白-代谢物”网络中STAT3 在LX-2和T6细胞中的蛋白表达进行实验验证。Western blotting结果分析显示 二氢丹参酮Ⅰ可以剂量依赖性地抑制LX-2细胞(图4C-a)中STAT3和p-STAT3 的表达,二氢丹参酮Ⅰ虽不能剂量依赖性地抑制T6细胞(图4C-b)中STAT3 的表达,但能明显的抑制其p-STAT3的表达。由于已有的研究显示,在治疗肝 纤维化过程中VEGFA、GCR、OTC的表达水平受到抑制(Salum GM,Bader El Din N G,Ibrahim M K,Anany M A,Dawood R M,Khairy A,El Awady M K.Vascular Endothelial Growth Factor Expression in Hepatitis C Virus-InducedLiver Fibrosis:A Potential Biomarker[J].Journal of interferon&cytokineresearch:the official journal of the International Society for Interferon andCytokine Research, 2017,37(7):310-6.Zhang C,Bian M,Chen X,Jin H,Zhao S,YangX,Shao J, Chen A,Guo Q,Zhang F,Zheng S.Oroxylin A prevents angiogenesis ofLSECs in liver fibrosis via inhibition of YAP/HIF-1alpha signaling[J].2018,119(2):2258-68. Wang L,Bell P,Morizono H,He Z,Pumbo E,Yu H,White J,Batshaw ML,Wilson J M.AAV gene therapy corrects OTC deficiency and prevents liverfibrosis in aged OTC-knock out heterozygous mice[J].Molecular genetics andmetabolism,2017, 120(4):299-305.Kim K H,Lee J M,Zhou Y,Harpavat S,Moore D D.Glucocorticoids Have Opposing Effects on Liver Fibrosis in Hepatic Stellateand Immune Cells[J].Molecular endocrinology(Baltimore,Md),2016,30(8): 905-16.)。因此,可以推断出二氢丹参酮Ⅰ通过与STAT3结合抑制其蛋白的 表达水平。
实施例3:二氢丹参酮Ⅰ改善了TAA诱导的肝损伤并降低了肝纤维化指 数
为了研究二氢丹参酮Ⅰ对肝功能的影响,检测血清肝功能标志物水平。 ALT、AST、ALT和γ-GT是反映肝脏生理功能的指标,当这些指标高于正常 值时表明肝功能出现不同程度的问题。如图5A/B/C/D所示,与对照组相比, 模型组血清中ALT、AST、ALT和γ-GT的值显著增加,表明模型组大鼠的肝 脏已被损伤。与模型组相比,二氢丹参酮Ⅰ给药组可以显著地降低大鼠血清中 ALT、AST、ALT和γ-GT的值,显示出二氢丹参酮Ⅰ具有一定保肝的功效,且二氢丹参酮Ⅰ高剂量组保肝比低剂量组功效略好;与阳性药索拉非尼组相 比,二氢丹参酮Ⅰ改善肝功能效果要比阳性药组好。
H&E染色测定结果证明模型组大鼠的肝脏组织结构已严重受损,观察到 有大量的肝细胞坏死和脂肪滴、新胆管形成。与正常对照组相比,二氢丹参酮 Ⅰ给药组显著地减少了这些病理变化(图5E)。天狼星红染色可以将胶原蛋 白可视化,用于评估纤维化的程度和特征。在模型组中(图5F),天狼星红 染色的胶原原纤维不仅延伸到门静脉区域,还延伸到肝实质;从图5F中发现 二氢丹参酮Ⅰ给药组中染色区域显著减少,表明二氢丹参酮Ⅰ可以减轻肝脏中 胶原蛋白的积累。正常肝脏中的胶原蛋白主要由IV与VI型组成;而肝损伤后, 由于基质代谢发生变化,胶原转变成I与III型胶原蛋白(Olaso E,Ikeda K,Eng F J,Xu L,WangL H,Lin H C,Friedman S L.DDR2 receptor promotes MMP-2-mediated proliferationand invasion by hepatic stellate cells[J].The Journal of clinicalinvestigation,2001,108(9):1369-78.刘蒲芳.柔肝灵颗粒对肝 纤维化模型大鼠血清TGF-β1和Ⅰ、Ⅲ型胶原的影响[D];陕西中医药大学;陕 西中医学院,2008.)。所以对肝脏中Ⅰ型和Ⅲ型胶原纤维面积进行数据统计如 图5G/H,数据分析后发现二氢丹参酮Ⅰ可以降低肝脏中Ⅰ型和Ⅲ型胶原纤维 的积累,且其效果比阳性药索拉非尼组好。这些数据表明二氢丹参酮Ⅰ可以改 善由TAA诱导的肝损伤,并具有改善肝功能、降低肝损伤和治疗肝纤维化的作用。
以上已对本发明创造的较佳实施例进行了具体说明,但本发明创造并不限 于所述实施例,熟悉本领域的技术人员在不违背本发明创造精神的前提下还可 做出种种的等同的变型或替换,这些等同的变型或替换均包含在本申请权利要 求所限定的范围内。
Claims (10)
1.二氢丹参酮Ⅰ在制备P53激动剂和信号传导及转录激活因子3抑制剂中的应用。
2.二氢丹参酮Ⅰ在制备P53激动剂中的应用。
3.二氢丹参酮Ⅰ在制备信号传导及转录激活因子3抑制剂中的应用。
4.二氢丹参酮Ⅰ在制备促进肝星状细胞凋亡,抑制肝星状细胞活化和增殖的药物中的应用。
5.根据权利要求4所述的二氢丹参酮Ⅰ在制备促进肝星状细胞凋亡,抑制肝星状细胞活化和增殖的药物中的应用,其特征在于,二氢丹参酮Ⅰ通过作用P53和STAT3,促进肝星状细胞凋亡,抑制肝星状细胞活化和增殖。
6.二氢丹参酮Ⅰ在制备降低肝脏中Ⅰ型和Ⅲ型胶原纤维的积累的药物中的应用。
7.二氢丹参酮Ⅰ作为P53激动剂在制备肝纤维化治疗药物中的应用。
8.二氢丹参酮Ⅰ作为信号传导及转录激活因子3抑制剂在制备肝纤维化治疗药物中的应用。
9.二氢丹参酮Ⅰ作为P53激动剂在制备动脉粥样硬化、乳腺癌、或结肠癌治疗药物中的应用。
10.二氢丹参酮Ⅰ作为信号传导及转录激活因子3抑制剂在制备膀胱癌、食管癌、或前列腺癌治疗药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910585525.9A CN110613708A (zh) | 2019-07-01 | 2019-07-01 | 二氢丹参酮ⅰ用作p53激动剂和信号传导及转录激活因子3抑制剂的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910585525.9A CN110613708A (zh) | 2019-07-01 | 2019-07-01 | 二氢丹参酮ⅰ用作p53激动剂和信号传导及转录激活因子3抑制剂的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110613708A true CN110613708A (zh) | 2019-12-27 |
Family
ID=68921673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910585525.9A Pending CN110613708A (zh) | 2019-07-01 | 2019-07-01 | 二氢丹参酮ⅰ用作p53激动剂和信号传导及转录激活因子3抑制剂的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110613708A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115212218A (zh) * | 2022-06-14 | 2022-10-21 | 天津中医药大学 | 一种二氢丹参酮i在抑制血小板和肿瘤细胞相互作用中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105213405A (zh) * | 2015-11-05 | 2016-01-06 | 中国医学科学院医药生物技术研究所 | 二氢丹参酮i在制备抗肝纤维化药物中的应用 |
-
2019
- 2019-07-01 CN CN201910585525.9A patent/CN110613708A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105213405A (zh) * | 2015-11-05 | 2016-01-06 | 中国医学科学院医药生物技术研究所 | 二氢丹参酮i在制备抗肝纤维化药物中的应用 |
Non-Patent Citations (2)
Title |
---|
宋烨: "丹参中丹参酮I和二氢丹参酮I的抗肿瘤活性及作用机制研究", 《中国优秀博硕士学位论文全文数据库(硕士) 医药卫生科技辑》 * |
郝文慧 等: "丹参酮类抗肿瘤作用与机制研究进展", 《中国药理学通报》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115212218A (zh) * | 2022-06-14 | 2022-10-21 | 天津中医药大学 | 一种二氢丹参酮i在抑制血小板和肿瘤细胞相互作用中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Lipopolysaccharide-induced toll-like receptor 4 signaling in cancer cells promotes cell survival and proliferation in hepatocellular carcinoma | |
Bohrer et al. | Macrophages promote fibroblast growth factor receptor-driven tumor cell migration and invasion in a CXCR2-dependent manner | |
Ghosh et al. | CXCR4 regulates migration of lung alveolar epithelial cells through activation of Rac1 and matrix metalloproteinase-2 | |
Giannelli et al. | Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma | |
Zhang et al. | The autoregulatory feedback loop of microRNA-21/programmed cell death protein 4/activation protein-1 (MiR-21/PDCD4/AP-1) as a driving force for hepatic fibrosis development | |
Wang et al. | Hyaluronic acid oligosaccharides improve myocardial function reconstruction and angiogenesis against myocardial infarction by regulation of macrophages | |
Wu et al. | To reveal pharmacological targets and molecular mechanisms of curcumol against interstitial cystitis | |
Yoo et al. | Orientin inhibits HMGB1-induced inflammatory responses in HUVECs and in murine polymicrobial sepsis | |
Nemeth et al. | Heme oxygenase-1 in macrophages controls prostate cancer progression | |
Lv et al. | Zoledronic acid inhibits thyroid cancer stemness and metastasis by repressing M2-like tumor-associated macrophages induced Wnt/β-catenin pathway | |
Jiang et al. | Hepatoprotective mechanism of Silybum marianum on nonalcoholic fatty liver disease based on network pharmacology and experimental verification | |
Tao et al. | Salvianolic acid B inhibits hepatic stellate cell activation through transforming growth factor beta-1 signal transduction pathway in vivo and in vitro | |
Zhu et al. | Antimetastatic Effects of Celastrus orbiculatus on Human Gastric Adenocarcinoma by Inhibiting Epithelial–Mesenchymal Transition and NF-κB/Snail Signaling Pathway | |
Tang et al. | PSC-derived Galectin-1 inducing epithelial-mesenchymal transition of pancreatic ductal adenocarcinoma cells by activating the NF-κB pathway | |
Zhang et al. | Interleukin-6 suppression reduces tumour self-seeding by circulating tumour cells in a human osteosarcoma nude mouse model | |
Coperchini et al. | TNF-α increases the membrane expression of the chemokine receptor CCR6 in thyroid tumor cells, but not in normal thyrocytes: potential role in the metastatic spread of thyroid cancer | |
Li et al. | Human splenic TER cells: A relevant prognostic factor acting via the artemin‐GFRα3‐ERK pathway in pancreatic ductal adenocarcinoma | |
Chu et al. | COE inhibits vasculogenic mimicry by targeting EphA2 in hepatocellular carcinoma, a research based on proteomics analysis | |
Fan et al. | Recent advances of the function of sphingosine 1‐phosphate (S1P) receptor S1P3 | |
Succar et al. | Formation of tight junctions between neighboring podocytes is an early ultrastructural feature in experimental crescentic glomerulonephritis | |
Xu et al. | Targeting Tumor Microenvironment: Effects of Chinese Herbal Formulae on Macrophage‐Mediated Lung Cancer in Mice | |
Li et al. | Interferon regulatory factor-2 binding protein 2 ameliorates sepsis-induced cardiomyopathy via AMPK-mediated anti-inflammation and anti-apoptosis | |
Song et al. | Gecko crude peptides induce apoptosis in human liver carcinoma cells in vitro and exert antitumor activity in a mouse ascites H22 xenograft model | |
Umeyama et al. | Anti-inflammatory effects of Morus alba Linne bark on the activation of toll-like receptors and imiquimod-induced ear edema in mice | |
Srivastava et al. | Interleukin-6 induced proliferation is attenuated by transforming growth factor-β-induced signaling in human hepatocellular carcinoma cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191227 |
|
RJ01 | Rejection of invention patent application after publication |